BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27871278)

  • 1. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer.
    Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
    BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer].
    Li G; Gu RM; Wen X; Ming XZ; Xia L; Xu XY; Zhang J; Chen HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jul; 16(7):668-72. PubMed ID: 23888453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
    Tovey SM; Witton CJ; Bartlett JM; Stanton PD; Reeves JR; Cooke TG
    Breast Cancer Res; 2004; 6(3):R246-51. PubMed ID: 15084248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ; Reeves JR; Going JJ; Cooke TG; Bartlett JM
    J Pathol; 2003 Jul; 200(3):290-7. PubMed ID: 12845624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients.
    Memon AA; Sorensen BS; Meldgaard P; Fokdal L; Thykjaer T; Nexo E
    Br J Cancer; 2006 Jun; 94(11):1703-9. PubMed ID: 16685269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
    Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
    Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.
    Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma.
    Almadori G; Coli A; De Corso E; Mele DA; Settimi S; Di Cintio G; Brigato F; Scannone D; Carey TE; Paludetti G; Lauriola L; Ranelletti FO
    J Transl Med; 2021 Sep; 19(1):408. PubMed ID: 34579737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
    Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
    Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.
    Yonemori K; Tsuta K; Shimizu C; Hatanaka Y; Hirakawa A; Ono M; Kouno T; Katsumata N; Ando M; Tamura K; Hasegawa T; Kinoshita T; Fujiwara Y
    J Surg Oncol; 2010 Mar; 101(3):222-7. PubMed ID: 20087905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-family gene amplification and expression in resected pancreatic cancer.
    te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
    Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
    Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G;
    Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.